ABSTRACT: Diseases triggered by an abnormally high level of cortisol (hypercortisolism), such as the Cushing's and metabolic syndromes, could be successfully tackled by inhibitors of CYP11B1, a steroidal cytochrome P450 enzyme that catalyzes the last hydroxylation step of the cortisol biosynthesis. Structural optimization of 7-(benzyloxy)-4-(1H-imidazol-1-ylmethyl)-2H-chromen-2-one 2, a selective aromatase inhibitor, afforded the 4-(1H-imidazol-1-ylmethyl)-7-{[3-(trifluoromethoxy)benzyl]oxy}-2H-chromen-2-one 7, with improved inhibitory potency at human CYP11B1 (IC 50 = 5nM) and an enhanced selectivity over human CYP11B2 (SIB = 25) compared to lead compound 2 (IC 50 = 72nM, SIB=4.0) and metyrapone (IC 50 = 15 nM, SIB= 4.8), a non-selective drug used in the therapy of the Cushing's syndrome. Structure-activity relationship studies allowed the design and optimization of a novel series of potent and selective compounds, that can be regarded as open analogues of 2H-chromen-2-one derivatives.
Discovery of New 7-Substituted-4-Imidazolylmethyl Coumarins

Introduction
Cytochromes P450 (CYPs) are iron-containing monooxygenase enzymes (hemoproteins) that catalyze the oxidation of exogenous and endogenous organic substances. CYPs play a pivotal role in the metabolism of xenobiotics, and drugs in particular, being responsible for their bio-activation, -toxification, -detoxification and total-body clearance processes. [1] Moreover, CYPs regulate the biosynthesis of endogenous molecules, including steroid hormones that in many diseases are over-produced and sustain the growth of cancer cells, as in estrogen-and androgen-dependent breast and prostate tumours, or induce visceral obesity, hypertension, and diabetes as in the Cushing's and metabolic syndromes outlined by an excessive production of cortisol (hypercortisolism). [2] Indeed potent and selective inhibitors of targeted CYPs have been extensively pursued and many efficient drugs discovered. Aromatase (CYP 19) [3] [4] [5] and 17β-hydroxylase/17,20-lyase (CYP17) [6] inhibitors are well known examples of CYPs inhibitors largely used in breast and prostate cancer, respectively (Chart 1). More recently, two additional CYP enzymes, namely, steroid 11β-hydroxylase (CYP11B1) [7] [8] [9] [10] and aldosterone synthase (CYP11B2), [11] [12] [13] both involved in the biosynthesis of corticosteroid hormones, have been exploited as possible druggable targets. CYP11B1 catalyzes the last step of cortisol biosynthesis, that is the hydroxylation of 11-deoxycortisol to cortisol, whereas CYP11B2 catalyzes the conversion of 11-deoxycorticosterone to corticosterone, 18-hydroxycorticosterone and finally to aldosterone (Scheme 1).
Scheme 1 .Biosynthesis of Cortisol and Aldosterone from Cholesterol.
Selective CYP11B1 inhibitors may therefore represent potential therapeutic agents for those pathologies characterized by an over-production of cortisol, like the Cushing's and metabolic syndromes. [14, 15] Although metyrapone (Chart2), a strong inhibitor of CYP11B1, is in clinical use for the treatment of Cushing's syndrome, its low selectivity over aldosterone synthase CYP11B2 and the consequent block of aldosterone biosynthesis leading to severe hypokalemia and water retention, limits its therapeutic applicability. [16, 17] Consequently, nowadays more selective CYP11B1 inhibitors are eagerly pursued. Unfortunately, the discovery of highly selective CYP11B1 inhibitors is not a simple task because the two CYP enzymes present a very high sequence homology and, moreover, the lack of experimental 3D models prevents the use of structure-based approaches for the design of potent and selective inhibitors. Pharmacophore and 3D QSAR models have been recently developed, [18] [19] [20] [21] but the relatively limited molecular diversity explored might preclude their sound application in the design of completely novel and selective inhibitors. Despite these objective drawbacks, careful evaluation of the structure-activity and structureselectivity relationships (SAR and SSR, respectively) allowed the discovery of potent and highly selective CYP11B2 [22] [23] [24] [25] [26] and potent but slightly selective CYP11B1 inhibitors. [7] [8] [9] [10] Two of the best compounds discovered in recent studies (e.g., A [8] and B [14] in Chart2) displayed very good to moderately potent CYP11B1 inhibition (IC 50 = 2 and 107 nM, respectively) and moderate selectivity indices (SIB= 13.3 and 16.5, respectively; SIB= IC 50 CYP11B2/IC 50 CYP11B1) but greater than that observed for metyrapone (SIB= 4.8) . [14] To discover novel and more potent CYP11B1 inhibitors, with a higher selectivity over CYP11B2, and CYP17 and CYP19 as well, a new research project was conceived stemming from 7-substituted-4-imidazolylmethyl coumarins recently reported by us as potent CYP19 inhibitors with high selectivity over CYP17. [27, 28] Chart 2. Chemical structures of potent and moderately selective CYP11B1 (see Table 2 ).
Chemistry
Already published coumarin derivatives 2-8, 10, 11, 13, 17 and 18 [28] were prepared from 4-chloromethyl-7-hydroxycoumarin through the benzylation of its phenolic group followed by the nucleophilic displacement of the chloro atom with imidazole, according to the reaction pathway illustrated in Scheme 2.
Results in Table 2 nicely support our intuition showing that our design of more potent and selective CYP11B1 inhibitors was successful. Unfortunately the compounds maintained a good inhibition of CYP19 and therefore the CYP11B1 over CYP 19 selectivity was low as assessed by selectivity indices SIC (SIC = IC 50 CYP19/IC 50 CYP11B), which were always <10 with the exception of the 3-and 4-trifluoromethoxy-and the 4-isopropoxy-benzyloxy derivatives 7, 11 and 15 ( SIC= 41, 19 and 12, respectively).
A rapid glance at the IC 50 and SI data span and distribution (Table 2 ) revealed the exploration of a limited range of affinity and selectivity, despite the appropriate span of lipophilic, electronic and steric parameters of the selected substituents. Unfortunately, while the derivation of reliable QSAR models was precluded, highly significant insights were gained from the analysis of the salient features of SAR and SSR.
Inhibitory potency at the CYP11B2 was always lower than that observed at the CYP11B1 (SIB>1) with the exception of the para-nitrobenzyloxyderivative 12 which presented an IC 50 at CYP11B2 equal to 86nM vs 111nM at CYP11B1 (SIB= 0.78).
The meta-substituted-benzyloxy derivatives 6, 7 and 8 resulted the most active CYP11B1 inhibitors (IC 50 = 20, 5 and 20 nM, respectively) being the meta-trifluoromethoxy derivative 7 the most potent inhibitor of the whole examined series of molecules. Lipophilic and electron-withdrawing meta substituents in compounds 3-9 increased the inhibitory potency of lead compound 2 whereas a similarly clear trend was not observed for the para-substituted benzyloxyderivatives 10-16 which were slightly less potent than the corresponding meta-substituted congeners. Interestingly, as for the meta derivatives, the para-trifluoromethoxybenzyloxy derivative 11 was the most potent CYP11B1 inhibitor (IC 50 = 20nM) within this sub-series of compounds whereas the bulky and highly lipophilic phenetyloxy derivative 16 showed the lowest inhibition at the CYP11B1 (IC 50 = 258nM). The di-substituted benzyloxy derivatives 17, 18 and 19 and the trimethoxybenzyloxy-derivative 20 displayed comparable affinity at CYP11B1 regardless the substitution pattern and the lipophilic and electronic characters of the substituents.
To further improve potency and selectivity and to gain further insights on the SAR and SSR, a small series of (3')4'-benzyloxy-2-imidazolyl-acetophenone derivatives 21-26, that can be seen as open and more flexible analogues of the examined coumarin derivatives ( Chart 3), was designed, prepared and tested along with the 4'-pyrydynylmethoxy-2-imidazolyl-acetophenone derivative 27. As shown in Chart 4 coumarins and open analogues did share a number of putative pharmacophoric elements.
Chart 3.
Design of "open coumarin analogues": removal of molecular rigidity.
Meta-benzyloxy derivative 21 resulted almost inactive at the four tested CYPs whereas the parabenzyloxy lead compound of this series (22) showed a moderate inhibitory activity at the CYP11B1 (IC 50 = 149nM) and a poor selectivity over CYP11B2 (SIB= 3.9). The lower CYP11B1 inhibitory activity of compound 21 compared to its regioisomer 22 can be easily interpreted by a structural comparison with the active coumarin analogue 2 indicating a perfect overlay of putative pharmacophoric elements with compound 21 (Chart 4) that was not observed with compound 22 represented in two different low
The high structural analogy between the coumarins and the open analogues (see Charts 3 and 4) led to hypothesize a similar binding mode at both CYP11B1 and CYP11B2. However, some different interactions did take place at the two enzyme binding sites as proved by the good selectivity displayed by a number of inhibitors, e.g., 23, 7, and 11. As these compounds were characterized by the presence of hydrophobic and electron-withdrawing substituents, one may speculate that hydrophobic and polar interactions favoured by electron-withdrawing groups (π-π interactions?) might trigger different interaction energies at the two likely different binding sites Finally, to evaluate the possibility to progress some of our compounds towards pre-clinical selected physicochemical and pharmacokinetic parameters were estimated by QikProp [29] for compounds 2, 7, 22 and 23 ( 
Conclusions
Cushing's syndrome, a disease characterized by an excessive production of cortisol, is generally treated with metyrapone, a non-selective CYP11B1 inhibitor. The lack of selectivity over CYP11B2 and other cytochromes P450, such as CYP19 and CYP17, bring about unwanted and severe side effects that strongly limit the therapeutic use of metyrapone.
The discovery of more potent and selective CYP11B1 inhibitors was one of the main goal reached in the present work. Structural optimizations of 7-benzyloxy coumarin derivative 2 led to compound 7 that exhibited an outstanding potency at CYP11B1 (IC 50 = 5nM) and good selectivity over CYP11B2 and CYP19 (SIB= 25 and SIC= 41, respectively) that represented a net improvement over metyrapone (IC 50 = 15nM; SIB= 4.8). Moving from the coumarin derivatives to the benzyloxybenzoylmethyl imidazole analogues afforded the potent CYP11B1 inhibitor 23 (IC 50 = 15nM) that showed a further improvement of the selectivity index over CYP11B2 (SIB= 33). Very interestingly, this compound exhibited also a very high selectivity over CYP19 (SIC= 390) and an extremely high selectivity over CYP17, which was not significantly inhibited (5%) at 2.5µM concentration. Its interesting potency and selectivity profiles, may warrant further in vitro and in vivo investigation in animal model of Cushing's syndrome.
Finally, the limited, but significant insights gained in the analysis of the SAR and SSR might drive further optimizations of compound 7 and 23 and suggest appropriate scaffold hopping from coumarins to other bicyclic and/or tricyclic heteroaromatics advocated also by the safety concerns recently raised on coumarins-containing biological active agents. [30] [31] [32] We are currently working along such a research line and the results will be presented in due course. The purity of all the intermediates, checked by 1 H NMR and HPLC, was always better than 90%. Purity of all the tested final products, determined by analytical HPLC by means of a peak area normalization method, was always greater than 95% (). Reverse phase HPLC analyses were performed on a system equipped with automatic injector and a Waters Breeze 1525 high performance liquid chromatography (HPLC) pump coupled with a Waters 2489 UV Detector (Waters Corporation, Milford, MA) using a Waters XTerra RP 5 μm C8 column (150 mm × 3.0 mm i. d.). The UV detection was measured at 254 and 280 nm. Each tested compound was analyzed by elution with two different mobile phase systems: in system 1, compounds were eluted using a 80/20 methanol/water mixture at a flow rate of 0.5 mL/min; in system 2, compounds were eluted using a 65/35 acetonitrile/water mixture at a flow rate of 0.5 mL/min.
Experimental section Chemistry
General procedure for the synthesis of 7-(1H-imidazol-1-ylmethyl)coumarin derivatives 9, 12, 14-16, 19 and 20 7-Hydroxy-4-imidazolylmethyl coumarin (0.242 g, 1.0 mmol) was dissolved in anhydrous THF (3 mL), and then the appropriate benzyl alcohol (1.20 mmol) was added followed by PPh 3 (0.315 g, 1.20 mmol). The solution was cooled to 0°C through an external ice bath, and a solution of DIAD (0.236 mL, 1.20 mmol) in anhydrous THF (2 mL) was added dropwise. The reaction was slowly warmed to room temperature and stirred for 18 h. The solvent was removed under reduced pressure, and the resulting crude mixture was purified by flash column chromatography (DCM/ MeOH: 9.5/0.5) and the obtained residue was crystallized from absolute ethanol.
4-((1H-Imidazol-1-yl)methyl)-7-((3-methoxybenzyl)oxy)-2H-chromen-2-one 9
Yield: 69%. Mp: 146-148 °C. Imidazol-1-yl) General procedure for the preparation of 4'(or 3')-phenyl(pyridinyl)methoxy-2-imidazolylacetopehenones 21-27.
4-((1H-
Intermediate 21a or 22a (0.050 g, 0.25 mmol) was dissolved in absolute EtOH (10 ml) and subsequently the appropriate arylmethyl bromide (0.38 mmol) and K 2 CO 3 (0.051 g, 0.38 mmol) was added. The reaction was kept at reflux for 6 h under stirring. After cooling, the precipitate was filtered off, and the solution was evaporated to dryness. The crude product was purified by flash column chromatography (DCM/MeOH: 9/1). 
1-(3-(
CYP11B1 and CYP11B2 Inhibition Assay
V79MZh11B1 and V79MZh11B2 cell lines were cultivated in Dulbecco's modified Eagle medium (DMEM, Sigma) supplemented with 5% of fetal calf serum (FCS; Sigma), penicillin (100 U/ml), streptomycin (100 µg/ml), glutamine (2 mM) and sodium pyruvate (1 mM) at 37°C in 5% CO2 in air.
V79MZ cells expressing human CYP11B1 and human CYP11B2 genes, respectively, were grown on 24-well cell culture plates (8 x 105 cells per well) with 1.9 cm² culture area per well in 1 ml DMEM culture medium until confluence. Before testing, the DMEM culture medium was removed and 450 µl of fresh DMEM, containing 1% of the ethanolic dilution of the inhibitor, was added to each well. Controls were treated in the same way without inhibitors. Every value was determined in duplicate. After a preincubation step of 60 min at 37°C, the reaction was started by the addition of 50 µl of DMEM containing the substrate 11-deoxycorticosterone (containing 0.15 µCi of [1,2- 3 H] 11-deoxycorticosterone, final concentration 100 nM).
The V79MZh11B1 cells were incubated for 25 min, the V79MZh11B2 cells were incubated for 45 min. The ethanol concentration in each well was 1%.
Enzyme reactions were stopped by extracting the supernatant with ethyl acetate. Samples were centrifuged (10000 x g, 10 min), and the solvent was pipetted into fresh cups. The solvent was evaporated and the steroids were redissolved in 40 µl of methanol and analyzed by HPLC.
CYP17 Inhibition Assay.
Briefly, human CYP17 and rat P450 reductase are expressed in E. coli [33] 140 µl phosphate buffer (50 mM sodium phosphate, 1 mM MgCl2, 0.1 mM EDTA, 0.1 mM dithiothreitol, pH 7.4), 50 µl NADPH generating system (in phosphate buffer with 10 mM NADP+, 100 mM glucose-6-phosphate and 0.5 units glucose-6-phosphate dehydrogenase), 5 µl of a mixture of progesterone and The steroids are extracted with 1 ml ethyl acetate (10 min shaking, followed by 5 min of centrifugation at 12500 rpm). 900 µl supernatant are transferred into new cups and washed with 250 µl phosphate buffer plus 50 µl 1 N HCl (10 min shaking, followed by 5 min of centrifugation at 12500 rpm). 800 µl are transferred into new cups. After evaporation of the ethyl acetate (SpeedVac), the steroids are redissolved in 40 µl methanol (100%). 16β-Hydroxyprogesterone, 17β-hydroxyprogesterone and progesterone are separated by HPLC using a C18 chromatography column (CC 125/3 Nucleodur 100-3 C-18 ec column, Macherey-Nagel, Düren) connected to a HPLCsystem (Agilent 1100 Series, Agilent Technologies, Waldbronn). HPLC conditions are as follows: Eluent A is 0.1% trifluoroacetic acid in water, eluent B is methanol (100%). Eluent flow rate is set to0.5 ml/min. Elution with 75% eluent B in the first 2 min is followed by a 2.5 min phase with 100% eluent B. From minute 4.5 -8.5 the eluent system is changed back to the original composition of 75% eluent B. Detection and quantification of 16β-hydroxyprogesterone (first peak), 17β-hydroxyprogesterone (second peak) and progesterone (third peak) are performed using a radioflow detector (Raytest GmbH, Straubenhardt). 
Preparation of aromatase:
The enzyme was obtained from the microsomal fraction of freshly delivered human term placental tissue according to the procedure of Thompson and Siiteri. [34] The isolated microsomes were suspended in a minimum volume of phosphate buffer (0.05 M, pH 7.4, 20 % glycerol). Additionally, DTT (dithiothreitol, 10 mM) and EDTA (1mM) were added to protect the enzyme from degradation.The enzyme preparation was stored at -70°C.
Inhibition of aromatase:
The assay was performed monitoring enzyme activity by measuring the 3H2O formed from [1β-3 H]androstenedione during aromatization. Each incubation tube contained 15 nM [1β-3 H]androstenedione (0.08 µCi), 485 nM unlabeled androstenedione, 2 mM NADP, 20 mM glucose-6-phosphate, 0.4 units of glucose-6-phosphate-dehydrogenase and inhibitor (in at least three different concentrations for determining the IC50 value) in phosphate buffer (0.05 M, pH 7.4). The test compounds were dissolved in DMSO and diluted with buffer. The final DMSO concentration in the control and inhibitor incubation was 2 %. Each tube was preincubated for 5 min at 30°C in a water bath. Microsomal protein was added to start the reaction (0.1 mg). The total volume for each incubation was 0.2 ml. The reaction was terminated by the addition of 200 µl of a cold 1 mM HgCl2 solution. After addition of 200 µl of an aqueous dextran-coated charcoal (DCC) suspension (2 %), the vials were shaken for 20 min and centrifuged at 1500 x g for 5 min to separate the charcoal-absorbed steroids. The supernatant was assayed for 3H2O by counting in a scintillation mixture using a β-counter. The calculation of the IC50 values was performed by plotting the percent inhibition vs. the concentration of inhibitor on a semi-log plot. From this the molar concentration causing 50 % inhibition was calculated.
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